Safety and Efficacy of Nipocalimab in Adults With Generalized Myasthenia Gravis (Vivacity-MG3)
Dr. Aaron Zelikovich discusses a recent article on nipocalimab and its role in treating generalized myasthenia gravis. Show citations: Antozzi C, Vu T, Ramchandren S, et al. Safety and efficacy of…
Read the full articleYou might also wanna read
EAN 2026: Positive trial data for cemdisiran underscores potential for use in generalized MG, says GlobalData
On June 30, at the 12th Congress of the European Academy of Neurology (EAN) 2026, Regeneron announced the results from an additional analysi
Sexual and Urinary Dysfunctions in Generalized Myasthenia
Conditions : Myasthenia Gravis (MG) Interventions : Other: No intervetion Sponsors : Centre Hospitalier Universitaire de Nice Not yet recrui
Unequal Access to New Myasthenia Gravis Therapies Across Europe Highlights Healthcare Disparities
New therapies are changing what is possible in generalised myasthenia gravis care, yet unequal access across Europe continues to hold patien
euractiv.com·21d agoMegan’s Myasthenia Gravis Story: From Uncertainty to Advocacy
I was diagnosed with myasthenia gravis, or MG, in 2021 when I was in my early 20s. My journey began at a friend’s birthday party when I noti
European Commission Expands Approval of Novartis Gene Therapy for Broader SMA Population
As reported on Pharmaceutical Technology, the European Commission has approved Novartis’ gene replacement therapy Itvisma (onasemnogene abep
Real-world data point to patient experience as next battleground for anti-CD20 therapies in RMS, says GlobalData
As real-world evidence (RWE) increasingly shapes competition in the relapsing multiple sclerosis (RMS) market, TG Therapeutics is leaning on
Comments
Sign in to join the conversation.
No comments yet. Be the first.